ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

MediLink Therapeutics (Suzhou) and Amgen side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

MediLink Therapeutics (Suzhou)Amgen
studies on the registry231,088
open to participants now1850
phase 3 studies under way750
reach primary completion within a year935
programswith a study of their own in two years524

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMediLink Therapeutics (Suzhou)Amgen
Phase 1

MediLink Therapeutics (Suzhou): 1 of its 5 programs at phase 1

  1. Anti-CDH17 Antibody-drug Conjugate YL217phase 1
20%

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%
Phase 2

MediLink Therapeutics (Suzhou): 2 of its 5 programs at phase 2

  1. aflutinibphase 2
  2. Anti-VEGF Antibody-drug Conjugate YL242phase 2
40%

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%
Phase 3

MediLink Therapeutics (Suzhou): 2 of its 5 programs at phase 3

  1. tambotatug pelitecanphase 3
  2. beruzatatug pelitecanphase 3
40%

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%
Approved, new studies00%

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
MediLink Therapeutics (Suzhou)2 readouts · 0 phase 3

MediLink Therapeutics (Suzhou), Nov ’26: 1 program whose next study reaches primary completion

  1. beruzatatug pelitecanphase 3 · Nov 0 · NCT06107686
·

MediLink Therapeutics (Suzhou), Jan ’27: 1 program whose next study reaches primary completion

  1. tambotatug pelitecanphase 3 · Jan 0 · NCT07208773
·········
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

MediLink Therapeutics (Suzhou)

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 5

Where they overlap

Conditions where at least two of them have programs: 7 in all. A program counts in each condition its studies name most.

ConditionMediLink Therapeutics (Suzhou)Amgen
Carcinoma, Non-Small-Cell Lungboth · compare here

MediLink Therapeutics (Suzhou) in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. tambotatug pelitecanphase 3
  2. beruzatatug pelitecanphase 3
  3. aflutinibphase 2

Their studies: MediLink Therapeutics (Suzhou)’s studies of Carcinoma, Non-Small-Cell Lung in search

Amgen in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. sotorasibphase 3
  2. Pan-KRAS Inhibitor AMG 410phase 1
  3. tambotatug pelitecanphase 1
  4. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

Small Cell Lung Carcinomaboth · compare here

MediLink Therapeutics (Suzhou) in Small Cell Lung Carcinoma: 1 program

  1. tambotatug pelitecanphase 3

Their studies: MediLink Therapeutics (Suzhou)’s studies of Small Cell Lung Carcinoma in search

Amgen in Small Cell Lung Carcinoma: 4 programs

  1. tarlatamabphase 3
  2. etakafusp alfaphase 1
  3. tambotatug pelitecanphase 1
  4. Zocilurtatug Pelitecanphase 1

Their studies: Amgen’s studies of Small Cell Lung Carcinoma in search

Neoplasmsboth · compare here

MediLink Therapeutics (Suzhou) in Neoplasms: 1 program

  1. Anti-VEGF Antibody-drug Conjugate YL242phase 2

Their studies: MediLink Therapeutics (Suzhou)’s studies of Neoplasms in search

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

Esophageal Squamous Cell Carcinomaboth · compare here

MediLink Therapeutics (Suzhou) in Esophageal Squamous Cell Carcinoma: 1 program

  1. tambotatug pelitecanphase 3

Their studies: MediLink Therapeutics (Suzhou)’s studies of Esophageal Squamous Cell Carcinoma in search

Amgen in Esophageal Squamous Cell Carcinoma: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Esophageal Squamous Cell Carcinoma in search

Nasopharyngeal Carcinomaboth · compare here

MediLink Therapeutics (Suzhou) in Nasopharyngeal Carcinoma: 1 program

  1. tambotatug pelitecanphase 3

Their studies: MediLink Therapeutics (Suzhou)’s studies of Nasopharyngeal Carcinoma in search

Amgen in Nasopharyngeal Carcinoma: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Nasopharyngeal Carcinoma in search

Neoplasm Metastasisboth · compare here

MediLink Therapeutics (Suzhou) in Neoplasm Metastasis: 1 program

  1. aflutinibphase 2

Their studies: MediLink Therapeutics (Suzhou)’s studies of Neoplasm Metastasis in search

Amgen in Neoplasm Metastasis: 1 program

  1. WRN Inhibitor AMG 436phase 1

Their studies: Amgen’s studies of Neoplasm Metastasis in search

Pancreatic Neoplasmsboth · compare here

MediLink Therapeutics (Suzhou) in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 3

Their studies: MediLink Therapeutics (Suzhou)’s studies of Pancreatic Neoplasms in search

Amgen in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Pancreatic Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: MediLink Therapeutics (Suzhou) 5 of 5 · Amgen 17 of 24 programs (20 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.